产品
编 号：F286374
分子式：C25H29N5O4S
分子量：495.59
分子式：C25H29N5O4S
分子量：495.59
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2355377-13-6
产品详情
生物活性：
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer.
体内研究：
DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group.DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency.Animal Model:Mice
Dosage:0~80 mg/kg
Administration:P.o.
Result:Showed a moderate effect at the high dose group.
体外研究：
DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47.
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer.
体内研究：
DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group.DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency.Animal Model:Mice
Dosage:0~80 mg/kg
Administration:P.o.
Result:Showed a moderate effect at the high dose group.
体外研究：
DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备